Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB)

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Shares of Cellectar Biosciences reverse split on the morning of Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences Inc (NASDAQ:CLRB) issued its earnings results on Monday, August, 12th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.70) by $0.24. View Cellectar Biosciences' Earnings History.

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Cellectar Biosciences.

3 equities research analysts have issued 1 year price objectives for Cellectar Biosciences' stock. Their forecasts range from $3.00 to $11.00. On average, they expect Cellectar Biosciences' share price to reach $6.6667 in the next twelve months. This suggests a possible upside of 174.3% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

Media headlines about CLRB stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectar Biosciences earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Cellectar Biosciences.

Cellectar Biosciences saw a decline in short interest in the month of August. As of August 15th, there was short interest totalling 403,300 shares, a decline of 5.3% from the July 15th total of 425,700 shares. Based on an average daily volume of 461,000 shares, the short-interest ratio is presently 0.9 days. Approximately 8.7% of the company's stock are short sold. View Cellectar Biosciences' Current Options Chain.

Some companies that are related to Cellectar Biosciences include Humanigen (HGEN), Marinus Pharmaceuticals (MRNS), Millendo Therapeutics (MLND), AgeX Therapeutics (AGE), Iterum Therapeutics (ITRM), Trevena (TRVN), Tiziana Life Sciences (TLSA), Helix Biopharma (HBPCF), Ovid Therapeutics (OVID), Mersana Therapeutics (MRSN), vTv Therapeutics (VTVT), Entasis Therapeutics (ETTX), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT) and Trevi Therapeutics (TRVI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (9.79%), Tang Capital Management LLC (7.24%), CVI Holdings LLC (1.13%) and Morgan Stanley (0.38%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor, John Neis and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

CLRB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Cellectar Biosciences.

CLRB stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Tang Capital Management LLC and CVI Holdings LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLRB stock can currently be purchased for approximately $2.43.

Cellectar Biosciences has a market capitalization of $22.83 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

The official website for Cellectar Biosciences is http://www.cellectar.com/.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]